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EGF receptor tyrosine kinase inhibition attenuates the devel-
opment of PKD in the Han:SPRD rats.
Background. Increasing evidence supports an important role
for the epidermal growth factor (EGF)/transforming growth
factor-alpha (TGF-)/EGF receptor (EGFR) axis in promoting
tubular epithelial cell proliferation and cyst formation in poly-
cystic kidney disease (PKD).
Methods. To determine whether the inhibition of EGFR tyro-
sine kinase activity can attenuate the development of PKD in
the Han:SPRD rat, a frequently used animal model of autoso-
mal-dominant slowly progressive PKD (ADPKD), wild-type
and cy/ rats were treated with EKI-785 or EKB-569 or with
vehicle alone. Western analysis, immunoprecipitation, and im-
munohistochemistry were used to ascertain the expression, ac-
tivation, and localization of EGFR.
Results. Overexpression, activation and apical mislocaliza-
tion of EGFR were observed in the cy/ rats. The intraperito-
neal administration of EKI-785 reversed the activation of the
EGFR to the level observed in wild-type animals. The intra-
peritoneal administration of EKI-785 (90 mg/kg body weight
every third day) or of EKB-569 (20 mg/kg body weight every
third day) to cy/ rats resulted in lower kidney weights, serum
concentrations of blood urea nitrogen (BUN), cyst volumes,
and fibrosis scores. The administration of EKB-569 by gavage
was less effective probably because of lower bioavailability.
Conclusion. These results support a significant role for the
EGF/TGF-/EGFR axis in the development of PKD in the
Han:SPRD rat and the therapeutic potential of EGFR tyrosine
kinase inhibition in ADPKD.
Autosomal-dominant polycystic kidney disease (ADPKD)
and autosomal-recessive polycystic kidney disease (ADPKD)
are leading causes of end-stage renal failure in adults
and in children. At present, only symptomatic treatment
is available, but recent advances in the understanding of
their molecular genetics and cellular pathophysiology
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give hope for more effective therapies [1, 2]. Evidence
from a number of laboratories has provided strong sup-
port for an important role of the epidermal growth factor
(EGF)/transforming growth factor-alpha (TGF-)/EGF
receptor (EGFR) axis in promoting tubular epithelial
cell proliferation and cyst formation. Although the renal
expression of EGF mRNA and protein is down-regu-
lated in cpk and pcy [3–5] mice and in Han:SPRD rats
[6], renal cyst fluids from ADPKD, ARPKD, and murine
and rat models of polycystic kidney disease (PKD) con-
tain EGF-like peptides in mitogenic concentrations [7–9].
The expression of TGF- mRNA and protein is in-
creased in ADPKD kidneys [10, 11]. EGF and TGF-
are cystogenic in a variety of in vitro systems [12–14].
Transgenic overexpression of TGF- [15], Erb-B2 [16]
(an EGFR-related tyrosine kinase receptor) and T24ras
[17] (a transduction molecule in the EGFR signaling
pathway) all result in renal cyst development in mice.
EGFR and Erb-B2 [18–21] are overexpressed and mislo-
calized to the apical membrane of the cystic epithelium
in human ADPKD and ARPKD and in murine models
of these diseases. These abnormally expressed apical re-
ceptors are capable of high-affinity EGF binding and
autophosphorylation and initiate a signaling cascade that
results in cell proliferation [20]. Finally, genetic and/or
pharmacologic inhibition of EGFR tyrosine kinase activ-
ity in vitro and/or in vivo markedly inhibits the develop-
ment of cystic disease [22, 23] in the bpk and orpk mice,
two models of autosomal-recessive, rapidly progressive
renal cystic disease. The purpose of this study was to
extend these observations to a frequently used animal
model of autosomal-dominant, slowly progressive renal
cystic disease, the Han:SPRD rat [24, 25].
METHODS
Experimental animals and study design
The male offspring of heterozygous Han:SPRD breed-
ing pairs maintained at the animal facilities of the Mayo
Torres et al: EGFR tyrosine kinase inhibition in Han:SPRD rats1574
Clinic (Rochester, MN, USA) and Case Western Re-
serve University (Cleveland, OH, USA) were used for
these studies. The rats with homozygous disease (cy/cy)
were recognized at 1 week of age by the marked renal
enlargement and died of uremia at 3 to 4 weeks of age.
The male homozygous normal (/) and heterozygous
diseased (cy/) littermates were randomized into control
and experimental groups. Only male rats were used be-
cause the renal cystic disease is very mild in the female
animals [24, 25].
Intraperitoneal administration of EKI-785. At 3 weeks
of age, male/ and cy/Han:SPRD rats were divided
into two groups. One group was injected intraperitone-
ally with 90 mg/kg of EKI-785 every 3 days, between 3
and 10 weeks of age. This dosage was based on previous
pharmacodynamic studies of this compound in other rat
strains. The other group received vehicle alone (2%
Tween 80, 0.5% methylcellulose in water). During the
studies the rats were given a standard rat laboratory diet
containing 23% protein and water ad libitum.
Intraperitoneal administration of EKB-569. At 3 weeks
of age, male/ and cy/Han:SPRD were divided into
two groups. One group was injected intraperitoneally
with 20 mg/kg of EKB-569 every 3 days between 3 and 10
weeks of age. This dosage was based on previous phar-
macodynamic studies of this compound in other rat
strains. The other group was injected with vehicle alone
(2% Tween 80, 0.5% methylcellulose).
Enteral administration of EKB-569. At 3 weeks of age
male / and cy/ Han:SPRD were divided into one
control and three experimental groups. The experimen-
tal groups were administered 5, 10, or 20 mg/kg of EKB-
569 by gavage daily, using a 24 gauge, 1 inch, stainless
steel fitting tube with 1.25 mm bulb tip between 3 and
10 weeks of age. The control group received vehicle (2%
Tween 80, 0.5% methylcellulose) alone.
EGFR tyrosine kinase inhibition. EKI-785 is a small
molecule inhibitor specific for EGFR tyrosine kinase
[26]. This compound binds irreversibly to the adenosine
triphosphate (ATP) binding site of EGFR, inhibits the
kinase activity of this protein, blocks EGFR autophos-
phorylation, inhibits cell proliferation, and blocks the
growth of tumors that overexpress EGFR. It also inhib-
its Erb-B2 activity. The duration of EKI-785 activity is
dependent on the half-life of the compound and the
turnover rate of EKI-785–bound EGFR in the plasma
membrane. Preliminary experiments demonstrated that
administration of EKI-785 intraperitoneally every 3 days
resulted in optimal inhibition with minimal toxicity.
EKB-569 is a derivative of EKI-785 with improved phar-
macokinetics and enteral bioavailability compared to the
parent compound [27].
Experimental protocol. At 10 weeks of age, the animals
were weighed and anesthetized with ketamine 60 mg/kg
and xylazine 10 mg/kg, intraperitoneally. Blood was ob-
tained by cardiac puncture for determination of serum
blood urea nitrogen (BUN) levels. The right kidney and
liver were placed into preweighed vials containing 4%
paraformaldehyde or 10% formaldehyde in phosphate
buffer (pH 7.4). The tissues were embedded in Immuno-
bed plastic embedding medium (Polysciences, Worthing-
ton, PA, USA) or in paraffin for histologic studies. The
left kidney was immediately frozen in liquid nitrogen for
Western blotting analysis and determination of tyrosine
kinase activity.
Histomorphometric analysis and immunohistology
For light microscopy, 5 m transverse tissue sections,
including cortex, medulla, and papilla were stained with
hematoxylin-eosin and picrosirius red. Hematoxylin-
eosin–stained sections were used to determine cyst vol-
ume densities. In the Han:SPRD rat, cyst volumes were
measured in the cortex, randomly selecting 10 fields (20)
at variable angles from the hilum of each section to guard
against field selection bias. Renal fibrosis was scored
using the picrosirius red staining of collagen fibers. Image
analysis procedures were performed with MetaMorph
software (Universal Imaging, West Chester, PA, USA).
The MetaMorph software system includes a light micro-
scope with a color digital camera (Nikon DXM 1200) and
a Pentium IBM-compatible computer (Del OptiPlex).
Stained sections were visualized under a Nikon micro-
scope and digital images were acquired using a high-reso-
lution Nikon digital camera and displayed on the moni-
tor. Interactively applied techniques of enhancement were
used for a better definition of interested structures and
to exclude fields too damaged to be analyzed. A colored
threshold was applied at a level that separates cysts from
noncystic tissue and picrosirius red–positive material from
background in order to calculate the volumes of cysts or
fibrosis. The areas of interest were expressed as a per-
centage of total tissue. Because of day-to-day variability
in the intensity of staining, the processing for picrosirius
red staining of all tissue sections from the same experi-
ment was always done at the same time. Immunohisto-
chemical staining of EGFR was conducted using rabbit
polyclonal anti-EGFR (Cell Signaling Technology, Bev-
erly, MA, USA), as previously described [20].
Western blotting analysis
Protein was isolated from whole kidneys by homog-
enization in radioimmunoprecipitation assay (RIPA) buf-
fer with protease inhibitors. Thirty micrograms of to-
tal protein lysate were diluted in sodium dodecyl sulfate
(SDS)-reducing buffer (62.5 mmol/L Tris-HCL, pH 6.8;
25% vol/vol glycerol; 2% wt/vol, SDS; 0.01% wt/vol bro-
mophenol blue; and 5% vol/vol p-mercaptoethanol) and
subjected to SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) using a 12% separating gel. Samples were
transferred to a nitrocellulose membrane, treated with
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Fig. 1. Epidermal growth factor receptor
(EGFR) expression analyzed by Western
analysis and immunolocalization of EGFR in
the kidney of wild-type and cy/ Han:SPRD
rats. (A ) Immunoblot of proteins isolated
from wild-type and cy/ Han:SPRD kidneys
showing an increased expression of EGFR in
the cystic kidney. (B ) Basolateral localization
of EGFR in the tubules from untreated wild-
type rats (400). (C ) Apical localization of
EGFR in many dilated tubules from un-
treated cy/ rats (400).
blocking buffer (5% dry milk, 0.05% Tween 20), and
probed with rabbit polyclonal anti-EGFR antibody. Mem-
branes were washed, probed with peroxidase-conjugated
antirabbit immunoglobulin, treated with enhanced chemi-
luminescence (ECL) reagent (Amersham Pharmacia Bio-
tech, Piscataway, NJ, USA), and exposed to autoradiog-
raphy film.
Demonstration of receptor tyrosine kinase activity
Equal amounts of total protein (500 g of total cell
lysate, diluted to same volume) isolated from whole kid-
neys by homogenization, as described above, were incu-
bated with 5 g of anti-EGFR antibodies for 2 hours at
4C. After centrifugation, 100 uL of protein A/G plus
agarose, (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) were added to the supernatants to pull down resul-
tant antibody-antigen complexes. The samples were in-
cubated with gentle rocking overnight at 4C. Immuno-
precipitated proteins were collected by centrifugation,
washed, processed for SDS-PAGE, transferred to nitro-
cellulose membranes, probed with antiphosphotyrosine
antibodies (RC-20-HPRO, Transduction Laboratories,
Lexington, KY, USA), and detected by ECL (Amersham
Life Science).
Statistical analysis
Comparisons between groups were made using one-
way or two-way analysis of variance (ANOVA) with
least significant difference comparisons of the means or
Student t test as appropriate.
RESULTS
Renal expression and activity of EGFR
The total EGFR levels measured by Western analysis
in whole kidney protein lysates were higher in male cy/
Han:SPRD rats than in their wild-type littermates (Fig.
1A). The Western analysis results were confirmed by
the immunohistochemical studies. High levels of EGFR
expression were detected in the kidneys of cy/ Han:
SPRD rats regardless of treatment with EKI-785. Apical
localization of EGFR was detected in some cysts and di-
lated tubules (Fig. 1B and C) in the cy/ rats, while it
Fig. 2. Immunoblots of proteins from the kidneys of wild-type, un-
treated cy/, and EKI-785–treated cy/ Han:SPRD rats immunopre-
cipitated with epidermal growth factor receptor (EGFR) antibody and
detected with phosphotyrosine antibody. EGFR phosphorylation is in-
creased in cy/ (B ) compared to wild-type (A ) and EKI-785 treated
(C ) cy/ kidneys. Immunoblot of the same proteins after stripping the
membrane and probing with anti-EGFR antibody. Levels are increased
in cy/ (E and F ) compared to wild-type kidneys (D).
was exclusively basolateral in the wild-type rats. To deter-
mine whether the overexpression of EGFR in the Han:
SPRD cy/ rats was accompanied by activation of the re-
ceptor and to establish whether treatment with EKI-785
effectively inhibited receptor activation, whole kidney pro-
teins were immunoprecipitated with anti-EGFR anti-
bodies, resolved by SDS-PAGE, transferred to nitrocel-
lulose, and probed with antiphosphotyrosine antibodies.
These studies showed that the phosphorylated EGFR
levels in the cy/ Han:SPRD rats were markedly in-
creased compared to their wild-type littermates (Fig. 2).
In addition, administration of EKI-785 resulted in a re-
duction of phosphorylated EGFR in the cy/ rats toward
the level observed in the wild-type animals (Fig. 2).
Intraperitoneal administration of EKI-785
and EKB-569
The intraperitoneal administration of EKI-785 had a
significant protective effect on the development of the
renal cystic disease in male cy/ Han:SPRD rats, as re-
flected by lower kidney weights, serum concentrations
of BUN, cyst volumes, and fibrosis scores (Table 1 and
Fig. 3). The administration of EKI-785 was well toler-
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Table 1. Intraperitoneal administration of EKI-785 to male wild-type and cy/ Han:SPRD rats
/ Cy/
EKI-785 mg/kg body weight Control (N  11) 90 (N  7) P value Control (N  9) 90 (N 11) P value
Body weight g 332.622.1 321.727.6 0.427 346.639.5 320.536.25 0.163
Kidney weight % body weight 0.820.04 0.850.03 0.090 2.520.30 2.190.30 0.032
Liver weight % body weight 4.230.17 4.420.29 0.115 4.030.12 4.800.41 0.001
Serum blood urea nitrogen mg/dL 20.32.5 22.74.1 0.177 35.64.5 31.63.0 0.036
Kidney cyst index % 56.53.7 43.44.2 0.001
Kidney fibrosis score % 11.470.92 5.731.10 0.001
Fig. 3. Cross sections and representative tis-
sue sections (hematoxylin-eosin, 200) of the
kidneys from PCK control (A and C ) and
EKI-785–treated (B and D ) cy/ Han:SPRD
rats. The administration of EKI-785 signifi-
cantly reduced the severity of the cystic disease.
ated and did not cause growth retardation. The weight
of the liver was significantly higher in the treated cy/
rats than in those receiving the vehicle alone, but liver
function tests remained normal (results not shown)
and no inflammatory changes were detected on histo-
logic examination. The intraperitoneal administration of
EKB-569 was also well tolerated, did not cause growth
retardation, and had a similar protective effect to that
of EKI-785 on the development of PKD (Table 2).
Enteral administration of EKB-569
The administration of EKB-569 by gavage at a dose
of 20 mg/kg body weight every day was well tolerated
and had a slight protective effect on the development
of PKD in the cy/ rats as reflected by the lower kidney
weights and cyst volumes (Table 3). The administration
of EKB-569 at a dose of 10 mg/kg body weight also had
a slight protective effect on kidney volume. The adminis-
tration of a lower dose was ineffective. No significant ef-
fects were detected in the wild-type rats (results not shown).
DISCUSSION
The results of this study indicate that the development
of PKD in the Han:SPRD rat is associated with mislocal-
ization and activation of the EGFR and that pharmaco-
logic blockade of EGFR significantly attenuates the de-
velopment of the cystic disease as previously reported in
bpk mice [20, 23]. They are also consistent with the milder
cystic phenotype of orpk mice carrying a wa2 mutation,
Torres et al: EGFR tyrosine kinase inhibition in Han:SPRD rats 1577
Table 2. Intraperitoneal administration of EKB-569 to male wild-type and cy/ Han:SPRD rats
/ Cy/
EKB-569 mg/kg body weight Control (N  16) 20 (N 14) P value Control (N  10) 20 (N 15) P value
Body weight g 334.840.7 330.933.5 0.772 341.326.9 346.219.2 0.625
Kidney weight % body weight 0.750.07 0.800.06 0.068 1.930.38 1.530.26 0.012
Liver weight % body weight 4.140.34 4.410.42 0.068 4.180.26 4.440.63 0.174
Serum blood urea nitrogen mg/dL 20.32.5 22.74.1 0.177 31.46.6 27.24.4 0.070
Kidney cyst index % 40.010.7 30.48.8 0.005
Kidney fibrosis score % 9.001.48 7.612.02 0.050
Table 3. Enteral administration of EKB-569 to male cy/ Han:SPRD rats
Cy/
EKB-785 mg/kg body weight Control (N  24) 5 (N  16) 10 (N  22) 20 (N  20) P value
Body weight g 337.827.7 342.330.9 336.331.5 315.544.8 0.077
Kidney weight % body weight 2.170.38 2.020.31 1.990.19a 1.840.23a 0.004
Liver weight % body weight 4.210.26 4.230.41 4.020.18 4.511.08 0.385
Serum blood urea nitrogen mg/dL 33.94.9 31.45.3 33.65.1 30.78.2 0.557
Kidney cyst index % 39.15.7 42.09.0 39.03.9 32.26.9a 0.022
Kidney fibrosis score % 4.040.86 3.762.12 3.802.29 4.541.13 0.772
a vs. control P  0.05
a mutation that decreases the tyrosine kinase activity of
EGFR [22]. The parenteral administration of EKI-785
and EKB-569 also reduced the extent of interstitial
fibrosis in the Han:SPRD cy/ rats. This observation
is consistent with the reduction in interstitial fibrosis
following 5/6 nephrectomy or prolonged ischemia in
transgenic mice with targeted expression of a dominant-
negative EGFR [28].
Contrary to the bpk and orpk mice, in which the cysts
derive from the collecting ducts, most of the cysts in the
Han:SPRD rats are of proximal tubular origin [24, 25].
Although EGF and TGF- are mitogenic for proximal
tubular epithelial cells [29–31] and have been shown to
induce proximal tubular cyst formation in murine meta-
nephric organ cultures [13], the protective effect of the
EGFR tyrosine kinase inhibitors on the development
of PKD in the Han:SPRD rat may at first sight seem
surprising. EGFRs are abundantly expressed on the ba-
solateral membranes of the proximal tubular epithelial
cells [32]. However, EGF is secreted into the urine in
the thick ascending loop of Henle and in the distal convo-
luted tubule and may not have access to the receptors
in the proximal tubules [33, 34]. Several factors may
account for and contribute to the observed effects on
proximal tubular cystogenesis. Contrary to EGF, TGF-
is mainly localized in the proximal tubules where it may
exert an autocrine or paracrine effect (reviewed in [35]).
This is particularly important because TGF- has been
found to be up-regulated and EGF down-regulated in
all the models of PKD in which their expression has
been studied [3–6]. Basolateral secretion or transcytosis
of EGF by distal tubular segments or cysts may also al-
low access to the receptors in the proximal tubules. Fi-
nally, physiologic concentrations of angiotensin II, which
has no mitogenic action by itself, enhance the sensitivity
of proximal tubular epithelial cells to the mitogenic ef-
fects of EGF [29]. The interaction between EGF and
angiotensin II may underlie the protective effect of angio-
tensin I-converting enzyme inhibitors and angiotensin II
type 1 receptor blockers on the development of PKD in
Han:SPRD rats [36–38].
CONCLUSION
The Han:SPRD rat is a slowly progressive animal model
of autosomal-dominant renal cystic disease [24, 25]. The
beneficial effects of two EGFR tyrosine kinase inhibitors
confirm previous observations in two murine models of
autosomal-recessive rapidly progressive cystic disease,
the cpk and the orpk mice [22, 23]. These results are also
consistent with the increasing evidence for a role of the
EGFR pathway in a number of other pathologic condi-
tions characterized by epithelial cell proliferation, such
as acute tubular necrosis [39, 40], renal mass reduction
[41, 42], and renal cell carcinoma [43]. Unfortunately, the
bpk and orpk mice and the Han:SPRD rat do not have
a genetically homologous human counterpart. Recently,
we reported that EKI-785 and EKB-569 did not have a
protective effect in the PCK rat [abstract; Wang X et al,
J Am Soc Nephrol 12:547A, 2001], a rat model in which
the EGFR is neither overexpressed nor apically localized
in renal cysts. The PCK rat is an animal model of hepato-
renal fibropolycystic disease caused by a splicing muta-
tion (IVS35-2A→T) that skips exon 36 and leads to a
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frame shift in the rat ortholog Pkhd1, the gene mutated
in human ARPKD [44]. Further studies will be necessary
to clearly demonstrate the potential therapeutic role of
tyrosine kinase inhibition in the treatment of human
ADPKD or ARPKD.
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